GastroPlus在毒理领域的应用文章 （2012—2020）

导  读

凡默谷技术部精取了2012-2020年10月GastroPlus在毒理领域的应用文章28篇。

其中编号1-9的文章是2019年8月-2020年10月新增的文章。

希望对您的业务或专业学习有所帮助。内容如下：

1.   除草剂绿草定在哺乳动物中的药代动力学和代谢研究：评估对安全性的影响

Review of the pharmacokinetics and metabolism of triclopyr herbicide in mammals: Impact on safety assessments.

Bartels M, Brown C, Chung G, Chan M, Terry C, Gehen SC, Corvaro M. Regulatory Toxicology and Pharmacology. Volume 116, October 2020, 104714. IF=2.652

2.   结构和PK功能的类似物在开发和评估生理药代动力学PBPK模型中的应用

Application of structural and functional pharmacokinetic analogs for physiologically based pharmacokinetic model development and evaluation.

Ellison CA, Wu S. Regul Toxicol Pharmacol. Volume 114, July 2020. IF=2.652

3.  整合3D培养的HepaRG细胞的体外数据和生理药代动力学PBPK模型，评估对乙酰氨基酚的肝毒性

Integration of in vitro data from three dimensionally cultured HepaRG cells and physiologically based pharmacokinetic modeling for assessment of acetaminophen hepatotoxicity.

Zhang C, Zhang Q, Li J, Yu L, Li F, Li W, Li Y, Peng H, Zhao J, Carmichael PL, Wang Y, Peng S, Guo J. Regul Toxicol Pharmacol. Volume 114, July 2020. IF= 2.652

4.  评估化妆品中香豆素风险的新一代案例

A next generation risk assessment case study for coumarin in cosmetic products.

Baltazar MT, Cable S, Carmichael PL, Cubberley R, Cull TA, Delagrange M, Dent MP, Hatherell S, Houghton J, Kukic P, Li H, Lee MY, Malcomber S, Middleton AM, Moxon TE, Nathanail AV, Nicol B, Pendlington R, Reynolds GK, Reynolds J, White A, Westmoreland C. Toxicol Sci. 2020 Jul 1;176(1):236-252. IF= 3.703

5.  联合体外代谢组学和生理药代动力学建模考察万古霉素引发的肾毒性

New insights into the vancomycin‐induced nephrotoxicity using in vitro metabolomics combined with physiologically based pharmacokinetic modeling.

Haiyan Du, Zheng Li, Yi Yang, Xiao Li, Yongxiang We, Yang Lin, Xiaomei Zhuang. J Appl Toxicol. 2020;40:897–907. IF=2.997

6.  结合体外测试和生理药代动力学PBPK模型进行化学品的肝毒性评估–以曲格列酮作为案例研究

Integrating In Vitro Testing and Physiologically-Based Pharmacokinetic (PBPK) Modelling for Chemical Liver Toxicity Assessment – a Case Study of Troglitazone.

Yu L, Li H, Zhang C, Zhang Q, Guo J, Li J, Yuan H, Li L, Carmichael PL, Peng S.Environ Toxicol Pharmacol. Volume 74, February 2020, 103296. IF=3.292

7.  食品成分的安全性评估：毒性动力学方法的实用性和相关性

Food ingredient safety evaluation: Utility and relevance of toxicokinetic methods.

Kabadi SV, Zang Y, Fisher JW, Smith N, Whiteside C, Aungst J. Toxicol Appl Pharmacol. Volume 382, 1 November 2019, 114759. IF=3.347

8.  三环唑类杀菌剂口服后在啮齿类动物的ADME曲线：评估化合物对人类健康安全性的重要综述

The ADME profile of the fungicide tricyclazole in rodent via the oral route: A critical review for human health safety assessment.

Corvaro M, Bartels M. Regul Toxicol Pharmacol. Volume 108, November 2019, 104438. IF=2.652

9.  通过体外剂量-效应数据，整合药代动力学和体内暴露的信息，从而对化学品进行筛选和排序的分层方法

Tiered approaches for screening and prioritizing chemicals through integration of pharmacokinetics and exposure information with in vitro dose-response data.

Leonard JA, Tan YM. Computational Toxicology. Volume 12, November 2019, 100101. CiteScore=2.5

10.  双酚A的微小结构修饰变化导致HepG2细胞的强烈生理反应

Minor structural modifications of bisphenol A strongly affect physiological responses of HepG2 cells.

Padberg F, Tarnow P, Luch A, Zellmer S. Arch Toxicol. May 4, 2019. IF=5.059

11.  通过计算机预测的方法辅助开发和评估基于生理的动力学模型

In silico resources to assist in the development and evaluation of physiologically-based kinetic models.

Madden JC, Pawar G, Cronin MTD, Webb S, Tan YM, Paini A. Computational Toxicology. Mar 5, 2019. CiteScore=2.5

12.  通过体外-计算机模拟的方法预测药物在体内的性能

In vitro – in silico approach for the prediction of in vivo performance of drugs.

do Vale Correia C, de Sousa Vale NF, Urtti A, Yliperttula M. Eur J Pharm Sci. Feb 12, 2019. IF=3.616

13.  化妆品安全评估中毒理学关注内部阈值（iTTC）面临的挑战：化妆品欧洲iTTC研讨会的相关讨论要点

Challenges in working towards an internal threshold of toxicological concern (iTTC) for use in the safety assessment of cosmetics: Discussions from the Cosmetics Europe iTTC Working Group workshop.

Ellison CA, Blackburn KL, Carmichael PL, Clewell HJ 3rd, Cronin MTD, Desprez B, Escher SE, Ferguson SS, Gregoire SL, Hewitt NJ, Hollnagel HM, Klaric M, Patel A, Salhi S, Schepky A, Schmitt BG, Wambaugh JF, Worth A. Regul Toxicol Pharmacol. Jan 28, 2019. IF=2.652

14.  使用人体生物监测和毒代动力学数据评估操作者暴露于haloxyfop的PBTK模型

PBTK model for assessment of operator exposure to haloxyfop using human biomonitoring and toxicokinetic data.

Cooper AB, Aggarwal M, Bartels MJ, Morriss A, Terry C, Lord GA, Gant TW. Regul Toxicol Pharmacol. Dec 10, 2018. IF=2.652

15.  生理动力学模型在解决环境化学混合物中的作用-综述

Role of Physiologically Based Kinetic modelling in addressing environmental chemical mixtures – a review.

Desalegn A, Bopp S, Asturiol D, Lamon L, Worth A, Paini A. Computational Toxicology.  Oct 1, 2018. CiteScore=2.5

16.  用现代标准评价2-乙基己基丙烯酸酯的皮肤致癌性研究

Critical Evaluation of 2-Ethylhexyl Acrylate Dermal Carcinogenicity Studies Using Contemporary Criteria.

Murphy S, Ellis-Hutchings R, Finch L, Welz S, Wiench K. Toxicol Lett. Sep 15, 2018.IF=3.569

17.     用于高通量筛选中优先顺序和决策的体外到体内转化IVIVE

In vitro to in vivo extrapolation for high throughput prioritization and decision making.

Bell SM, Chang X, Wambaugh JF, Allen DG, Bartels M,et,al. Toxicol In Vitro. 2018 Mar;47:213-227. IF=2.959

18.  通过体外-体内转化评估毒代动力学TK

Evaluating In Vitro-In Vivo Extrapolation of Toxicokinetics.

John F Wambaugh, Michael F Hughes, Caroline L Ring, Denise K MacMillan, Jermaine Ford, Timothy R Fennell, et al. Toxicol Sci. 2018 May; 163(1): 152–169.IF=3.703

19.  考察基于生理学的动力学模型实操的状态，法规监管中模型应用面临的挑战

Investigating the state of physiologically based kinetic modelling practices and challenges associated with gaining regulatory acceptance of model applications.

Paini A, Leonard JA, Kliment T, Tan YM, Worth A. Regul Toxicol Pharmacol. Nov 1, 2017. IF=2.652

20.  整合生命阶段的生理药代动力学PBPK模型与不良结果通路（AOPs）和环境暴露模型，以筛选对环境的危害

Integration of Life-Stage Physiologically-Based Pharmacokinetic (PBPK) Models with Adverse Outcome Pathways (AOPs) and Environmental Exposure Models to Screen for Environmental Hazards.

El-Masri H, Kleinstreuer N, Hines RN, Adams L, Tal T, Isaacs K, Wetmore BA, Tan YM. (2016). Toxicol Sci. May 4. IF=3.564

21.  使用高通量的体外数据，高通量暴露模型，生理药代动力学/药效模型，估算甲状腺过氧化物酶抑制剂的体内暴露

Estimating Margin of Exposure to Thyroid Peroxidase Inhibitors Using High-throughput In Vitro Data, High-throughput Exposure Modeling, and Physiologically-Based Pharmacokinetic / Pharmacodynamic Modeling.

Leonard JA, Tan YM, Gilbert M, Isaacs K, El-Masri H. (2016) Toxicol Sci. Feb 10.IF=3.703

22.  聚乙二醇化的维生素Eγ-生育三烯酚异构体：合成，表征，体外细胞毒性和口服生物利用度

PEGylated y-tocotrienol isomer of vitamin E: Synthesis, characterization, in vitro cytotoxicity, and oral bioavailability.

Abu-Fayyad A, Behery F, Sallam A, Alqahtani S, Ebrahim H, El Sayed KA, Kaddoumi A, Sylvester PW, Carroll JL, Cardelli JA, Nazzal S. Eur J Pharm Biophar. Oct 1, 2015. IF=4.604

23.  通过机制性的ToxCast线粒体抑制数据和口服生物利用度的模拟，预测化合物在多个物种中的急性毒性

Acute toxicity prediction in multiple species by leveraging mechanistic ToxCast mitochondrial inhibition data and simulation of oral bioavailability.

Bhhatarai B, Wilson DM, Bartels MJ, Chaudhuri S, Price PS, Carney EW. Toxicol Sci.Oct 1, 2015. IF=3.703

24.  21世纪的毒性测试（TT21C）的实施：使用毒性途径进行安全决策并对原型进行风险评估取得的进展

Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment.

Adeleye Y, Andersen M, Clewell R, Davies M, Dent M, Edwards S, Fowler P, Malcomber S, Nicol B, Scott A, Scott S, Sun B, Westmoreland C, White A, Zhang Q, Carmichael PL. (2014). Toxicology, Feb 25. IF=4.099

25.  新的抗肿瘤吡唑衍生化合物的生物药剂学概况

Biopharmaceutical profiling of new antitumor pyrazole derivatives.

Anuta V, Nitulescu GM, Dinu-Pîrvu CE, Olaru OT. (2014) Molecules. Oct 13;19(10):16381-401. IF=3.267

26.  转化PK / PD模型，并用于评价候选药物的心血管安全性：药物开发中的方法和实例

Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development.

Caruso A, Frances N, Meille C, Greiter-Wilke A, Hillebrecht A, Lave T. (2014). J Pharmacol Toxicol Methods. May 28. IF=2.252

27.  新型LTA4H抑制剂在大鼠中的睾丸分布和毒性

Testicular distribution and toxicity of a novel LTA4H inhibitor in rats.

Ward PD, La D. (2014) Toxicol Appl Pharmacol. Apr 22;278(1):26-30. IF=3.347

28.  用于评估菊酯类杀虫剂对人体风险的QSAR和PBPK / PD模型的参数

Parameters for pyrethroid insecticide QSAR and PBPK/PD models for human risk assessment.

Knaak JB, Dary CC, Zhang X, Gerlach RW, Tornero-Velez R, Chang DT, Goldsmith R, Blancato JN. (2012) Rev. Environ. Contam. Toxicol. IF=5.767

点击查看其他文献

• GastroPlus在FDA等法规部门的应用文章(2016-2020)